Oncocross Co.,Ltd. Logo

Oncocross Co.,Ltd.

AI-powered biotech accelerating drug development for cancer and rare diseases.

382150 | KO

Overview

Corporate Details

ISIN(s):
KR7382150001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로11길 7 905호(문정동, 문정현대지식산업센터1-2), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oncocross Co., Ltd. is an AI-powered biotechnology company focused on innovating the drug development process. The company leverages its proprietary AI platforms, such as RAPTOR AI™, to analyze an extensive, medically curated transcriptome database of patient, drug, and disease gene expression data. This technology-driven approach enables the identification of optimal drug-disease indications, facilitates drug repositioning to discover new therapeutic uses, and aims to reduce the time, cost, and failure rates of clinical trials. Oncocross concentrates on developing treatments for intractable conditions, including cancers and rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제1회차 CB)
Korean 5.6 KB
2025-07-22 00:00
Share Issue/Capital Change
기타경영사항(자율공시) (상장주관사의 신주인수권행사)
Korean 8.7 KB
2025-07-21 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 77.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.0 MB
2025-04-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 355.0 KB
2025-04-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 30.5 KB
2025-04-15 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.9 KB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 366.6 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.0 KB
2025-03-28 00:00
Board/Management Information
대표이사변경
Korean 10.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-20 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 457.5 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.1 KB

Automate Your Workflow. Get a real-time feed of all Oncocross Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncocross Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncocross Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.